Algert Global’s ProQR Therapeutics PRQR Stock Holding History

Algert Global’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,665	Closed	-$8K	–	1247
2022 Q3	$8K	Hold	10,665	–	–	﹤0.01%	1154
2022 Q2	$8K	Sell	10,665 -645	-6%	-$481	﹤0.01%	1175
2022 Q1	$10K	Buy	+11,310	New	+$37.9K	﹤0.01%	1163
2021 Q3	–	Sell	-11,300	Closed	-$76K	–	1069
2021 Q2	$76K	Hold	11,300	–	–	0.03%	400
2021 Q1	$75K	Buy	+11,300	New	+$57.7K	0.02%	418

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Algert Global's PRQR Position: Q4 2022 in Review

Algert Global sold out of ProQR Therapeutics (PRQR) in Q4 2022, closing a stake of 10,665 shares — an estimated $8K sold.

Algert Global first reported a position in PRQR in Q1 2021 and held it in 5 quarters. The position peaked at $76K in Q2 2021. 46 funds tracked by Wall St. Rank hold PRQR as of Q4 2022.

Algert Global reported no remaining ProQR Therapeutics position as of Q4 2022 after selling out during the quarter.
Algert Global sold 10,665 ProQR Therapeutics shares in Q4 2022, an estimated $8K.
Algert Global first reported a position in ProQR Therapeutics in Q1 2021 and held it in 5 quarters.
Algert Global's ProQR Therapeutics position peaked at $76K in Q2 2021.
46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2022.

Based on Algert Global's 13F filing for Q4 2022, filed 14 Feb 2023.